Eli Lilly plans to invest $100 million in research and development in China over the next five years through Lilly Asian Ventures, a Lilly-owned venture capital firm that makes investments in Asia.
Indianapolis, IN (Nov. 14)-Eli Lilly plans to invest $100 million in research and development (R&D) in China over the next five years through Lilly Asian Ventures, a Lilly-owned venture capital firm that makes investments in Asia.
Lilly Asian Ventures was established in 2007 with a geographic focus on the emerging life-science businesses of east and south Asia, particularly China and India.
Earlier this year, Eli Lilly invested $10 million in BioVeda China (Shanghai), a venture capital fund focused on investment in the life-sciences in China.
In September 2007, Eli Lilly formed an R&D pact with Hutchison MediPharma (Shanghai) for the discovery and development of new clinical candidates in oncology and inflammation. Hutchison MediPharma will receive development milestone payments of $20–29 million per candidate and royalties upon commercialization of a candidate.
Eli Lilly also has a pact with Shanghai ChemExplorer (Shanghai), a contract research organization in China. The companies formed a collaborative R&D pact in 2002.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.